# PROfound (NCT02987543)

> Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

No report yet. It can be ordered.

- Drugs tested: olaparib
- Indication: metastatic castration-resistant prostate cancer with HRR alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02987543
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: olaparib; enzalutamide; abiraterone acetate; abiraterone acetate; enzalutamide
- Enrollment: 387
- Primary outcome: Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only

## Indexed commentary on PROfound so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=profound-nct02987543